NCT00789685View on ClinicalTrials.gov

Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Acute Lung InjuryAcute Respiratory Distress Syndrome
Interventions
DRUG

Interferon Beta

Interferon Beta administered intravenously daily for 6 days. Doses of 0.12 MIU, 1.2 MIU, 2.7 MIU or 6.0 MIU (dose escalation phase) or 2.7 MIU (dose expansion phase) were administered.

Trial Locations (8)

CG14 4XW

University Hospital of Wales, Cardiff

EH16 4SA

Edinburgh Royal Infirmary, Edinburgh

G11 6NT

Western Infirmary, Glasgow

G42 9TY

Victoria Infirmary, Glasgow

N19 5NF

Whittington Hospital, London

NW1 2BU

University College London Hospital, London

SE1 7EH

St Thomas' Hospital, London

W2 1NY

St Mary's Hospital, London

Sponsors
All Listed Sponsors
lead

Faron Pharmaceuticals Ltd

INDUSTRY

NCT00789685 - Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II | Biotech Hunter | Biotech Hunter